Bio-Techne entered a strategic partnership to distribute Spear Bio's innovative immunoassays targeting low-abundance neurology biomarkers relevant to Alzheimer's disease research, including phosphorylated tau 217, GFAP, and neurofilaments. Spear Bio’s Successive Proximity Extension Amplification Reaction (SPEAR) platform, licensed from Harvard University, leverages conventional qPCR instrumentation to produce highly sensitive assays. The collaboration aims to equip researchers with precise tools enhancing translational studies in neurodegenerative diseases, leveraging Bio-Techne’s global network and expertise. Bio-Techne previously invested in Spear Bio during its $45 million Series A funding round.